Drug intelligence / Profile preview

repatumab

Development stage: Preclinical
Lead developer: Shenzhou Cell Engineering
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

Repatumab is an investigational pharmaceutical drug developed by Shenzhou Cell Engineering Co. LTD for the management of Hemophilia A, particularly in patients with inhibitors, as part of Immune Tolerance Induction (ITI) therapy. It is administered intravenously. Based on the company's known pipeline for Hemophilia A, it is likely a recombinant Factor VIII product, aiming to replace the deficient coagulation factor VIII to improve blood clotting.

Other names: Repertumab

Targets

F8 (Coagulation Factor VIIIa)

Beyond the preview

Go deeper on repatumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on repatumab.

Explore the full profile